HC Wainwright Reiterates “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $77.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on CAPR. Wall Street Zen lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Roth Capital restated a “buy” rating and set a $31.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, June 17th. Oppenheimer dropped their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.57.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $10.05 on Tuesday. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40. The firm has a 50-day moving average price of $10.91 and a two-hundred day moving average price of $12.42. The firm has a market cap of $459.08 million, a price-to-earnings ratio of -7.08 and a beta of 0.84.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same period in the prior year, the company earned ($0.31) earnings per share. As a group, sell-side analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in CAPR. Charles Schwab Investment Management Inc. lifted its holdings in Capricor Therapeutics by 51.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 37,868 shares during the last quarter. Swiss National Bank purchased a new stake in shares of Capricor Therapeutics during the 4th quarter valued at approximately $930,000. Nuveen Asset Management LLC lifted its stake in shares of Capricor Therapeutics by 392.7% during the 4th quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company’s stock valued at $2,334,000 after buying an additional 134,791 shares in the last quarter. Alliancebernstein L.P. bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $183,000. Finally, The Manufacturers Life Insurance Company grew its stake in Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 2,361 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.